JP4598523B2 - 喘息に使用するｃ−ｍａｆ阻害剤としてのエンジアンドリック酸ｈ誘導体 - Google Patents

喘息に使用するｃ−ｍａｆ阻害剤としてのエンジアンドリック酸ｈ誘導体 Download PDF

Info

Publication number
JP4598523B2
JP4598523B2 JP2004526742A JP2004526742A JP4598523B2 JP 4598523 B2 JP4598523 B2 JP 4598523B2 JP 2004526742 A JP2004526742 A JP 2004526742A JP 2004526742 A JP2004526742 A JP 2004526742A JP 4598523 B2 JP4598523 B2 JP 4598523B2
Authority
JP
Japan
Prior art keywords
formula
acid
compound
plant
bale
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004526742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503006A (ja
JP2006503006A5 (https=
Inventor
クラウディア・エーダー
ヘルベルト・コグラー
ザビーネ・ハーグ−リヒター
ロバート・ウォーカー・シングルトン
アルン・スーブラマニアム
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006503006A publication Critical patent/JP2006503006A/ja
Publication of JP2006503006A5 publication Critical patent/JP2006503006A5/ja
Application granted granted Critical
Publication of JP4598523B2 publication Critical patent/JP4598523B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2004526742A 2002-08-02 2003-07-18 喘息に使用するｃ−ｍａｆ阻害剤としてのエンジアンドリック酸ｈ誘導体 Expired - Fee Related JP4598523B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10235624A DE10235624A1 (de) 2002-08-02 2002-08-02 Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
PCT/EP2003/007821 WO2004014888A1 (de) 2002-08-02 2003-07-18 Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma

Publications (3)

Publication Number Publication Date
JP2006503006A JP2006503006A (ja) 2006-01-26
JP2006503006A5 JP2006503006A5 (https=) 2006-08-31
JP4598523B2 true JP4598523B2 (ja) 2010-12-15

Family

ID=30469404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526742A Expired - Fee Related JP4598523B2 (ja) 2002-08-02 2003-07-18 喘息に使用するｃ−ｍａｆ阻害剤としてのエンジアンドリック酸ｈ誘導体

Country Status (13)

Country Link
US (1) US7019028B2 (https=)
EP (1) EP1529040B1 (https=)
JP (1) JP4598523B2 (https=)
AT (1) ATE314359T1 (https=)
AU (1) AU2003250099B2 (https=)
BR (1) BR0313199A (https=)
CA (1) CA2493483C (https=)
DE (2) DE10235624A1 (https=)
DK (1) DK1529040T3 (https=)
ES (1) ES2254980T3 (https=)
IL (1) IL166439A (https=)
MX (1) MXPA05000387A (https=)
WO (1) WO2004014888A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944361A1 (en) 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Also Published As

Publication number Publication date
BR0313199A (pt) 2005-06-21
IL166439A (en) 2009-12-24
MXPA05000387A (es) 2005-03-23
IL166439A0 (en) 2006-01-15
US7019028B2 (en) 2006-03-28
DE50302084D1 (de) 2006-02-02
EP1529040B1 (de) 2005-12-28
AU2003250099B2 (en) 2008-12-18
DE10235624A1 (de) 2004-02-19
JP2006503006A (ja) 2006-01-26
ES2254980T3 (es) 2006-06-16
ATE314359T1 (de) 2006-01-15
DK1529040T3 (da) 2006-05-08
CA2493483A1 (en) 2004-02-19
US20040138313A1 (en) 2004-07-15
AU2003250099A1 (en) 2004-02-25
CA2493483C (en) 2011-09-20
EP1529040A1 (de) 2005-05-11
WO2004014888A1 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
AU617139B2 (en) New phenylethanolamines
HU179172B (en) Process for producing phenethanolamine derivatives
JP4598523B2 (ja) 喘息に使用するｃ−ｍａｆ阻害剤としてのエンジアンドリック酸ｈ誘導体
CN108840871B (zh) 具有抗肿瘤活性的13-羟基金雀花碱肉桂酸酯类化合物及其制备方法
JPH07505118A (ja) ジャガイモシスト線虫用孵化剤
CN105994314A (zh) 骆驼宁碱a在防治蚜虫中的应用
RU2492173C2 (ru) Новые соединения со спирохиральной углеродной основой, способы их получения и фармацевтические композиции, содержащие такие соединения
JP4077723B2 (ja) クライネチンおよびその誘導体、調製方法および使用
CN117903049A (zh) 一种白藜芦醇衍生物及其制备方法和应用
CN111777588B (zh) 假臭草苯丙素类化合物及其应用
JP5170608B2 (ja) アフラトキシン生産阻害剤、及びそれを用いたアフラトキシン汚染防除方法
CN115583896A (zh) 一种香草酰胺类化合物、制备方法及应用
PL94963B1 (https=)
CN107382930B (zh) 化合物s-6-[羟基(苯基)甲基]-2h-吡喃-2-酮及其制剂和应用
CN115837036B (zh) 黑水虻提取物在制备水产动物寄生虫杀虫剂中的应用
CN102766146A (zh) 双呋喃二氢沉香呋喃醚类化合物及用于制备杀虫剂的应用
CN121181624A (zh) 一种新型生物碱类化合物Oreonudine G及其制备方法和应用
TW200529807A (en) Remedy
CN118978453A (zh) 根皮素衍生物及其制备方法和应用
CN110003033A (zh) 氟比洛芬查尔酮曼尼希碱类化合物、其制备方法和用途
JP3621495B2 (ja) 抗真菌剤
CN114591282A (zh) 从香青兰中分离得到的一个吡喃酮化合物及其制备方法与用途
KR20130034458A (ko) 벼 지상부 추출물, 벼 지상부 분획물, 이로부터 분리된 리그난 글리코시드 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물
CN118702696A (zh) 具有广泛生物学效应的细胞分裂素化合物及其制备方法和应用
CN119969410A (zh) 一种柯南因碱型生物碱在抗烟草花叶病毒中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100924

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131001

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees